Four patients with a single allografted kidney were given 1.0 mg of tritiated digoxin intravenously. Compared with patients with two normally functioning kidneys, these patients cxhibited increased digoxin serum levels, modestly reduced renal excretion, and increased stool excretion of digoxin during a 7-day study. This study was designed to determine the functional capacity of the denervated allografted human kidney to excrete tritiated digoxin and to compare these findings with previous studies in these same patients during the renoprival period. Comparisons will be made with previous studies in our laboratory on patients with normal renal function.2 Methods Tritiated digoxin was prepared by the Wilzbach hydrogen exchange method and had a specific activity of 66 to 112 ,tc/mg. A thin-layer radiochromatogram demonstrating the purity of the preparation, which was chemically pure, cardio-active, sterile, and pyrogen free, is shown in figure 1 .
the absence of urinary excretion and results in a prolonged serum half-time.
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Four patients, none of whom were in congestive heart failure, were given 1.0 mg of tritiated digoxin intravenously after renal transplant. One patient was studied twice-once 32 days after the transplant and again 224 days after it. All patients were receiving immunosuppressive agents at the time of the study. is 50 hours, and represents metabolism and excretion of digoxin. Line C represents the distribution and tissue binding of intravenous tritiated digoxin and has a half-time of 60 min. This turnover curve is compared with that obtained from the same patients when anephric, and a group of 12 patients with normal renal function and congestive heart failure in figure 2B . Note that serum levels of digoxin are highest during the anephric state with a dominant half-time of 82 hours, intermediate after transplantation with a half-time Radioactivity is plotted on the vertical axis as percentage of the 15-min specimen, on a semilogarithmic scale with time on the horizontal axis. Curve A represents the actual counting rates; line B represents an extension to zero time of curve A after the equilibration plateau was reached. This exponential indicates metabolism and excretion and has a half-time of 50 hours. Line C represents a second exponential function with a half-time of 60 min, representing tissue distribution and binding.
(B) Composite serum digoxin turnover. Radioactivity is plotted on a semilogarithmic scale on the vertical axis as in figure 2A; Figure 3 compares the 7-day urine excretion of digoxin in the same three groups as shown in figure 2 . There is, of course, no urinary excretion in the anephric patients, but there is 42% excretion in the post-transplant patients, and 80% in the patients with congestive heart failure and normal renal function. Figure 3 also shows the 7-day fecal excretion of tritiated digoxin in these same patients. Thirty-one percent of the total administered dose was excreted in 7 days in the stool of anephric patients, 21% in the post-transplant state, and 12% in patients with normal renal function after comparable doses of digoxin. The total digoxin excretion by these patients is indicated. Anephric patients who were maintained on dialysis excreted a total of only 34% of the total administered dose of digoxin in 7 days. After renal transplantation, these same patients excreted 63% of the digoxin over a similar period. These data are in contrast to the 92% excreted by patients with congestive failure and normal renal function. Table 1 lists each patient's age, sex, and dates of post-transplant study of blood urea nitrogen, serum potassium, and creatinine clearance. Table 2 indicates the excretion data and half-time of digoxin while the patients were anephric and after transplant.
Discussion
Digoxin, a polar digitalis glycoside, is excreted primarily by the kidney. Eighty percent of the administered dose of tritiated digoxin and its metabolites can be recovered from the urine during a 7-day collection period following intravenous administration into human subjects with congestive heart failure. A small amount, roughly 10 to 12%, is recovered from the stool in this same period of time. 2 Renal insufficiency has been shown to prolong digoxin excretion5-7 and may result in digitalis toxicity.9 Digoxin excretion can be related inversely to the level of the blood urea nitrogen (BUN) ,5 or proportionally to the creatinine clearance.7 Figure 4 illustrates the relationship of the BUN to digoxin clearance. Note the reduction in digoxin clearance when the BUN reaches 50 to 75 mg%.
The data which have been presented indicate that urinary excretion of digoxin in the allografted kidney was roughly proportional to that expected for a single kidney, 42% being 
